AJMC June 29, 2022
Research presented at the 2022 American Society of Clinical Oncology Annual Meeting shows White patients with myelodysplastic syndrome (MDS) have worse overall survival outcomes than African American patients, contrary to previous findings in other cancer types.
Disparities in cancer care and outcomes between African American patients and White patients have been demonstrated in past studies, with African American patients often experiencing worse outcomes. Regarding myelodysplastic syndrome (MDS), however, an abstract presented at the 2022 American Society of Clinical Oncology Annual Meeting shows White patients to have worse overall survival (OS) outcomes than African Americans patients.
MDS encompasses a group of clonal myeloid neoplasms first defined as malignant in 2001. The causes of MDS are often unknown, but in some cases,...
Today's Sponsors
Today's Sponsor